These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16079891)

  • 1. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
    Amadori S; Suciu S; Stasi R; Willemze R; Mandelli F; Selleslag D; Denzlinger C; Muus P; Stauder R; Berneman Z; Pruijt J; Nobile F; Cassibba V; Marie JP; Beeldens F; Baila L; Vignetti M; de Witte T
    Leukemia; 2005 Oct; 19(10):1768-73. PubMed ID: 16079891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
    Larson RA; Boogaerts M; Estey E; Karanes C; Stadtmauer EA; Sievers EL; Mineur P; Bennett JM; Berger MS; Eten CB; Munteanu M; Loken MR; Van Dongen JJ; Bernstein ID; Appelbaum FR;
    Leukemia; 2002 Sep; 16(9):1627-36. PubMed ID: 12200674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
    Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
    Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
    Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
    J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).
    Sievers EL
    Blood Cells Mol Dis; 2003; 31(1):7-10. PubMed ID: 12850477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
    Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
    Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
    Fenton C; Perry CM
    Drugs; 2005; 65(16):2405-27. PubMed ID: 16266206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab ozogamicin: a component of induction therapy in AML?
    Giles F
    Leuk Res; 2005 Jan; 29(1):1-2. PubMed ID: 15541468
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
    Sievers EL
    Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.
    Leone G; Rutella S; Voso MT; Fianchi L; Scardocci A; Pagano L
    Haematologica; 2004 May; 89(5):634-6. PubMed ID: 15136240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
    Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
    Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.